There are 2789 resources available
531P - Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Preliminary results of the investigator initiated phase II BEAVER trial
Presenter: April Rose
Session: ePoster Display
532P - Phase Ib study evaluating BI 836880 (VEGF/Ang2 nanobody) in combination with ezabenlimab (BI 754091; anti-PD-1 antibody) in patients with solid tumours
Presenter: Nicolas Girard
Session: ePoster Display
533P - Efficacy and safety of entrectinib in patients with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumours
Presenter: Lyudmila Bazhenova
Session: ePoster Display
534P - Larotrectinib in non-CNS TRK fusion cancer patients: Outcomes by prior therapy and performance status
Presenter: Alexander Drilon
Session: ePoster Display
535P - Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase (TRK) fusion cancer
Presenter: Marcia S. Brose
Session: ePoster Display
536P - Incidence of fractures in TRK fusion cancer patients treated with larotrectinib
Presenter: Theodore W. Laetsch
Session: ePoster Display
537P - Exposure-response analysis of cabozantinib in patients with metastatic renal cell cancer treated in routine care
Presenter: Stefanie Krens
Session: ePoster Display
539P - Interim results of a phase I study of M701, a recombinant anti-EpCAM and anti-CD3 bispecific antibody in EpCAM-positive cancer patients with malignant ascites
Presenter: Jianming Xu
Session: ePoster Display
540P - Safety and efficacy from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating a CD8α co-receptor and an affinity optimized TCR targeting MAGE-A4
Presenter: David Hong
Session: ePoster Display